Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,109,970
  • Shares Outstanding, K 49,092
  • Annual Sales, $ 31,940 K
  • Annual Income, $ -109,950 K
  • 60-Month Beta 2.50
  • Price/Sales 38.03
  • Price/Cash Flow N/A
  • Price/Book 5.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.64
  • Number of Estimates 4
  • High Estimate -0.56
  • Low Estimate -0.77
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +4.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.13 +12.32%
on 02/28/19
24.91 -9.23%
on 03/20/19
+2.74 (+13.79%)
since 02/22/19
3-Month
17.80 +27.02%
on 12/24/18
28.15 -19.68%
on 01/16/19
+4.42 (+24.30%)
since 12/21/18
52-Week
17.80 +27.02%
on 12/24/18
41.43 -45.43%
on 06/21/18
-15.39 (-40.50%)
since 03/22/18

Most Recent Stories

More News
S&P Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks

S&P Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks

SCVL : 30.74 (-3.27%)
CRSP : 35.59 (-6.00%)
TNDM : 68.76 (-6.53%)
UBNT : 144.27 (-2.08%)
TECD : 98.45 (-5.97%)
LASR : 22.39 (-3.12%)
FN : 51.37 (-5.62%)
ZS : 66.01 (-5.59%)
EDIT : 22.61 (-8.61%)
XPER : 23.09 (-5.02%)
INGN : 90.12 (-4.82%)
Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update

EDIT-101 for LCA10 set to be first ever in vivo CRISPR medicine administered to patients with dosing expected in second half of 2019

EDIT : 22.61 (-8.61%)
Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day(R)

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the Company is joining forces with the nearly 30 million Americans living with a rare disease and health care advocates...

EDIT : 22.61 (-8.61%)
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

QURE : 63.43 (-7.28%)
SLDB : 10.24 (-2.94%)
ONCE : 113.00 (-0.24%)
RGNX : 57.79 (-7.46%)
EDIT : 22.61 (-8.61%)
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?

Focus of Editas' (EDIT) fourth-quarter conference call is likely to be on its pipeline.

CELG : 88.15 (-1.65%)
BDSI : 5.11 (-3.58%)
AGN : 149.30 (-2.76%)
EDIT : 22.61 (-8.61%)
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study

CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study....

CRSP : 35.59 (-6.00%)
VRTX : 181.53 (-0.56%)
EDIT : 22.61 (-8.61%)
NTLA : 16.16 (-8.29%)
5 Gene Therapy Stocks to Enrich Your Portfolio

Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.

QURE : 63.43 (-7.28%)
SLDB : 10.24 (-2.94%)
ONCE : 113.00 (-0.24%)
RGNX : 57.79 (-7.46%)
EDIT : 22.61 (-8.61%)
RHHBY : 33.7600 (-1.06%)
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate...

GMDA : 11.93 (-0.09%)
EDIT : 22.61 (-8.61%)
Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know

Editas Medicine (EDIT) closed the most recent trading day at $19.86, moving -0.45% from the previous trading session.

EDIT : 22.61 (-8.61%)
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $19.75, marking a +1.65% move from the previous day.

EDIT : 22.61 (-8.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade EDIT with:

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 25.42
1st Resistance Point 24.02
Last Price 22.61
1st Support Level 21.87
2nd Support Level 21.12

See More

52-Week High 41.43
Fibonacci 61.8% 32.40
Fibonacci 50% 29.61
Fibonacci 38.2% 26.83
Last Price 22.61
52-Week Low 17.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar